Literature DB >> 24710571

LC-MS-based metabolomics: an update.

Zhong-Ze Fang1, Frank J Gonzalez.   

Abstract

Liquid chromatography-mass spectrometry (LC-MS)-based metabolomics can have a major impact in multiple research fields, especially when combined with other technologies, such as stable isotope tracers and genetically modified mice. This review highlights recent applications of metabolomic technology in the study of xenobiotic metabolism and toxicity, and the understanding of disease pathogenesis and therapeutics. Metabolomics has been employed to study metabolism of noscapine, an aryl hydrocarbon receptor antagonist, and to determine the mechanisms of liver toxicities of rifampicin and isoniazid, trichloroethylene, and gemfibrozil. Metabolomics-based insights into the pathogenesis of inflammatory bowel disease, alcohol-induced liver diseases, non-alcoholic steatohepatitis, and farnesoid X receptor signaling pathway-based therapeutic target discovery will also be discussed. Limitations in metabolomics technology such as sample preparation and lack of LC-MS databases and metabolite standards, need to be resolved in order to improve and broaden the application of metabolomic studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24710571      PMCID: PMC6310611          DOI: 10.1007/s00204-014-1234-6

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  17 in total

Review 1.  Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity.

Authors:  Frank J Gonzalez; Zhong-Ze Fang; Xiaochao Ma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-04-02       Impact factor: 4.481

2.  Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro.

Authors:  Cen Xie; Xiaoxia Gao; Dongxue Sun; Youbo Zhang; Kristopher W Krausz; Xuemei Qin; Frank J Gonzalez
Journal:  Drug Metab Dispos       Date:  2018-01-23       Impact factor: 3.922

3.  Metabolic pathway profiling of the derivative of important herbal component noscapine.

Authors:  Yonghua Yao; Yang Xiong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-10-22       Impact factor: 2.441

4.  Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G.

Authors:  Liu Xiaoyang; Ni Chenming; Li Chengqing; Liu Tao
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

5.  The therapy of gefitinib towards breast cancer partially through reversing breast cancer biomarker arginine.

Authors:  Dongmei Geng; Dengjun Sun; Liangming Zhang; Weiwei Zhang
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

Review 6.  Blood type biochemistry and human disease.

Authors:  D Rose Ewald; Susan C J Sumner
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-09-07

7.  Tracer-Based Cancer Metabolomic Analysis.

Authors:  Jianzhou Liu; Jing Huang; Gary Guishan Xiao
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Tryptophan-induced pathogenesis of breast cancer.

Authors:  Zhu-Gen Cao; Xiao-Bing Qin; Fang-Fang Liu; Lei-Lei Zhou
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

9.  Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement.

Authors:  Dorothea Lesche; Vilborg Sigurdardottir; Alexander B Leichtle; Christos T Nakas; Uwe Christians; Lars Englberger; Martin Fiedler; Carlo R Largiadèr; Paul Mohacsi; Johanna Sistonen
Journal:  Metabolomics       Date:  2017-11-25       Impact factor: 4.290

10.  Metabolic mapping of A3 adenosine receptor agonist MRS5980.

Authors:  Zhong-Ze Fang; Dilip K Tosh; Naoki Tanaka; Haina Wang; Kristopher W Krausz; Robert O'Connor; Kenneth A Jacobson; Frank J Gonzalez
Journal:  Biochem Pharmacol       Date:  2015-07-23       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.